Avaliação dos resultados clínicos de um serviço de gerenciamento da terapia medicamentosa ofertados a pacientes em tratamento do câncer de mama

Abstract

Adverse reactions resulting from the use of medications used by patients undergoing treatment for breast cancer compromise the safety and effectiveness of cancer treatment. To assist these patients, Medication Therapy Management (MTM) aims to identify, resolve and prevent Drug-related problems (DRP). The present study aimed to present the clinical results of a MTM service offered to patients undergoing treatment for breast cancer in the phases of neoadjuvant chemotherapy and hormone therapy as well as associated comorbidities. This is an almost experimental prospective study, carried out in the oncology sector of a hospital in Minas Gerais, Brazil, involving 76 patients (n = 76). The factors that caused the DRPs were evaluated, as well as the clinical results comparing the clinical and laboratory parameters obtained during the initial and final consultations. Based on the analysis of the collected data, there was a high rate of identification of PRM in the categories of safety (60.16%) and indication (33.33%), showing the impact that adverse reactions and untreated conditions generate on the success of pharmacotherapy. Among the main comorbidities present in the sample were osteopenia, dyslipidemia and diabetes. When comparing the laboratory indexes of the markers of these comorbidities before and after the follow-up by the MTM service, it was observed that the clinical pharmaceutical monitoring had a significant statistical impact on the levels of triglycerides, HDLc and vitamin D, in addition to reducing the global number of drugs in use per patient, showing prevention of polypharmacy. Thus, the present study shows that the MTM optimizes pharmacotherapy, generates clinical benefits and guarantees the safety and efficacy of the treatment.